Replies to post #131666 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

Despite touting A2-73 potential in ALZ and other CNS, AVXL did not have any deals - does it tell that BP do not have confidence in A2-73?

That is one possibility, another of course is that Anavex have the confidence to go it alone and don't want itself and it's shareholders be controlled by BP.

[riaguy]

I think that the science is showing promise but, that on the part of BP, there is no confidence in Missling

[seventhwave]

Awesome terms for a preclinical pipeline. IMO an incredibly dimwitted move by Abbvie in such a tough indication unless they have been shown incontrovertible evidence, (I can't start to imagine what might qualify as such.) My sense is they haven't as the protagonists are talking in high-level conceptual terms like "immuno-oncology of the brain." Something that doesn't seem revolutionary enough not to have been considered for postulation, ages ago.

Broadly speaking, to the extent Alzheimers arises from insults to the brain rather than fully endogenous reasons, focusing on the gatekeepers to the brain (in microglia) may be a worthy approach to slow down and keep away any onset. Don't think they are addressing mitochondrial repair and any receptor restoration that is essential for any reversal of the condition.

Haven't looked into the backgrounds of the 2 main protagonists but I get scared off when I see someone describe oneself as a serial-entrepreneur esp. if the person is primarily a medical researcher. I prefer the Tasos Zografidis types who confine themselves to research and leave profit-seeking motivation as a responsibility for someone else organizationally.

Never a bright move to buy in so early on an indication that's presented such remote a chance in clinically effective treatment. Could be totally wrong but my gut says it had a lot to do with connections.